Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
EvoPAR-BR01
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
1 other identifier
interventional
500
28 countries
294
Brief Summary
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Aug 2024
Longer than P75 for phase_3
294 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 25, 2024
CompletedFirst Posted
Study publicly available on registry
April 24, 2024
CompletedStudy Start
First participant enrolled
August 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 18, 2030
May 15, 2026
May 1, 2026
4.7 years
March 25, 2024
May 14, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Progression-Free Survival
PFS is defined as time from randomisation until progression per RECIST v1.1 as assessed by BICR, or death due to any cause.
Up to approximately 59 months
Secondary Outcomes (11)
Overall Survival
Up to approximately 88 months
Progression Free Survival 2
Up to approximately 59 months
Time to chemotherapy
Up to approximately 59 months
Objective Response Rate
Up to approximately 59 months
Duration of Response
Up to approximately 59 months
- +6 more secondary outcomes
Study Arms (3)
Arm 1: saruparib (AZD5305) plus camizestrant
EXPERIMENTALparticipants will receive saruparib (AZD5305) orally and camizestrant orally
Arm 2: Physician's choice CDK4/6i plus physician's choice ET
ACTIVE COMPARATORagents are indicated below and should follow local guidelines: * Physician's Choice CDK4/6i: * abemaciclib orally, or * ribociclib orally, or * palbociclib orally. * Physician's Choice ET: * fulvestrant intramuscularly, or * One of the following AIs: * letrozole orally, or * anastrozole orally, or * exemestane orally
Arm 3: Physician's choice CDK4/6i plus camizestrant
EXPERIMENTALparticipants will receive camizestrant orally. Agents for CDK4/6i treatment are indicated above and should follow local guidelines
Interventions
Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.
Camizestrant (AZD9833) is an orally bioavailable, next generation SERD with non-clinical and clinical activity in both ESR1 mutant and wild type settings .
CDK4/6 Inhibitor
CDK4/6 Inhibitor
CDK 4/6 Inhibitor
Eligibility Criteria
You may qualify if:
- Adult females, pre/peri-menopausal and/or post-menopausal, and adult males
- Histologically or cytologically documented diagnosis of HR-positive, HER2-negative breast cancer
- Advanced breast cancer with either locally advanced disease not amenable to curative treatment or metastatic disease
- ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks
- FFPE tumour tissue from each participant
- Documented germline tumour loss of function mutation in BRCA1, BRCA2, or PALB2
- Adequate organ and marrow function
You may not qualify if:
- Participants with history of MDS/AML or with features suggestive of MDS/AML
- Participants with any known predisposition to bleeding
- Any history of persisting severe cytopenia
- Any evidence of severe or uncontrolled systemic diseases or active uncontrolled infections
- Refractory nausea and vomiting, chronic GI disease, inability to swallow the formulated product, or previous significant bowel resection
- History of another primary malignancy
- Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy excluding alopecia
- Spinal cord compression, brain metastases, carcinomatous meningitis, or leptomeningeal disease
- Evidence of active and uncontrolled hepatitis B and/or hepatitis C
- Evidence of active and uncontrolled HIV infection
- Active tuberculosis infection
- Cardiac criteria, including history of arrythmia and cardiovascular disease
- Concurrent exogenous reproductive hormone therapy or non-topical hormonal therapy for non-cancer-related conditions
- Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study
- Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks before the first dose of study treatment
- +13 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (298)
Research Site
Gilbert, Arizona, 85234, United States
Research Site
Fountain Valley, California, 92708, United States
Research Site
Glendale, California, 91206, United States
Research Site
Los Angeles, California, 90089, United States
Research Site
Newport Beach, California, 92663, United States
Research Site
Aurora, Colorado, 80045, United States
Research Site
Grand Junction, Colorado, 81501, United States
Research Site
Hollywood, Florida, 33021, United States
Research Site
Jacksonville, Florida, 32224, United States
Research Site
Orlando, Florida, 32806, United States
Research Site
Chicago, Illinois, 60611, United States
Research Site
Evanston, Illinois, 60201, United States
Research Site
Park Ridge, Illinois, 60068, United States
Research Site
Urbana, Illinois, 61801, United States
Research Site
Winfield, Illinois, 60190, United States
Research Site
Indianapolis, Indiana, 46227, United States
Research Site
Louisville, Kentucky, 40207, United States
Research Site
Baltimore, Maryland, 21201, United States
Research Site
Silver Spring, Maryland, 20902, United States
Research Site
Silver Spring, Maryland, 20904, United States
Research Site
Boston, Massachusetts, 02215, United States
Research Site
Dearborn, Michigan, 48126, United States
Research Site
Detroit, Michigan, 48202, United States
Research Site
Royal Oak, Michigan, 48073, United States
Research Site
Royal Oak, Michigan, 48073, United States
Research Site
Rochester, Minnesota, 55905, United States
Research Site
Springfield, Missouri, 65804, United States
Research Site
St Louis, Missouri, 63110, United States
Research Site
Camden, New Jersey, 08103, United States
Research Site
New Brunswick, New Jersey, 08901, United States
Research Site
Brooklyn, New York, 11220, United States
Research Site
Mineola, New York, 11501, United States
Research Site
New Hyde Park, New York, 11042, United States
Research Site
New York, New York, 10016, United States
Research Site
New York, New York, 10028, United States
Research Site
New York, New York, 10065, United States
Research Site
Shirley, New York, 11967, United States
Research Site
Stony Brook, New York, 11790, United States
Research Site
The Bronx, New York, 10469, United States
Research Site
Westbury, New York, 11590, United States
Research Site
Hershey, Pennsylvania, 17033, United States
Research Site
Philadelphia, Pennsylvania, 19104, United States
Research Site
Pittsburgh, Pennsylvania, 15215, United States
Research Site
West Columbia, South Carolina, 29169, United States
Research Site
Chattanooga, Tennessee, 37404, United States
Research Site
Nashville, Tennessee, 37203, United States
Research Site
Houston, Texas, 77030, United States
Research Site
Houston, Texas, 77030, United States
Research Site
Houston, Texas, 77054, United States
Research Site
San Antonio, Texas, 78240, United States
Research Site
Norfolk, Virginia, 23502, United States
Research Site
Tacoma, Washington, 98405, United States
Research Site
Morgantown, West Virginia, 26506, United States
Research Site
Milwaukee, Wisconsin, 53215, United States
Research Site
Ciudad Autónoma Buenos Aires, 1125, Argentina
Research Site
Ciudad de Buenos Aires, 1015, Argentina
Research Site
Ciudad de Buenos Aires, C1280AEB, Argentina
Research Site
Córdoba, 5008, Argentina
Research Site
Rosario, S2000KZE, Argentina
Research Site
Salta, A4400EMI, Argentina
Research Site
San Miguel de Tucumán, 4000, Argentina
Research Site
Darlinghurst, 2010, Australia
Research Site
Darlinghurst, 2139, Australia
Research Site
Malvern, 3144, Australia
Research Site
Melbourne, VIC 3000, Australia
Research Site
Graz, 8036, Austria
Research Site
Innsbruck, 6020, Austria
Research Site
Linz, 4010, Austria
Research Site
Vienna, 1090, Austria
Research Site
Cachoeira de Itapemirim, 29308-055, Brazil
Research Site
Curitiba, 80060-900, Brazil
Research Site
Fortaleza, 60336-045, Brazil
Research Site
Goiânia, 74000-000, Brazil
Research Site
Jaú, 17210-120, Brazil
Research Site
Porto Alegre, 91350-200, Brazil
Research Site
Ribeirão Preto, 14049-901, Brazil
Research Site
Salvador, 41253-190, Brazil
Research Site
São Paulo, 01509-900, Brazil
Research Site
São Paulo, 03102-002, Brazil
Research Site
Plovdiv, 4002, Bulgaria
Research Site
Sofia, 1527, Bulgaria
Research Site
Stara Zagora, 6003, Bulgaria
Research Site
Vratsa, 3000, Bulgaria
Research Site
Toronto, Ontario, M5G 2M9, Canada
Research Site
Greenfield Park, Quebec, J4V 2G9, Canada
Research Site
Montreal, Quebec, H2X 0A9, Canada
Research Site
Montreal, Quebec, H3T 1E2, Canada
Research Site
Montreal, Quebec, H4A 3J1, Canada
Research Site
Saskatoon, Saskatchewan, S7N 4H4, Canada
Research Site
Toronto, M4N 3M5, Canada
Research Site
Providencia, 7500994, Chile
Research Site
Recoleta, 8420391, Chile
Research Site
Santiago, 8330034, Chile
Research Site
Talca, 3461341, Chile
Research Site
Viña del Mar, 2520000, Chile
Research Site
Beijing, 100044, China
Research Site
Bengbu, 233004, China
Research Site
Changchun, 130012, China
Research Site
Changchun, 130021, China
Research Site
Changsha, 410008, China
Research Site
Changsha, 410013, China
Research Site
Chengdu, 610000, China
Research Site
Chengdu, 610072, China
Research Site
Chongqing, 400042, China
Research Site
Foshan, 528000, China
Research Site
Fuzhou, 350014, China
Research Site
Guangzhou, 510060, China
Research Site
Guangzhou, 510062, China
Research Site
Guangzhou, 510289, China
Research Site
Hangzhou, 310016, China
Research Site
Hangzhou, 310022, China
Research Site
Harbin, 150081, China
Research Site
Hefei, 230031, China
Research Site
Hohhot, 010017, China
Research Site
Jining, 272029, China
Research Site
Kunming, 650118, China
Research Site
Liuzhou, 545006, China
Research Site
Luoyang, 471000, China
Research Site
Nanchang, 330006, China
Research Site
Nanchang, 330009, China
Research Site
Nanjing, 210029, China
Research Site
Shandong, 250117, China
Research Site
Shanghai, 200025, China
Research Site
Shanghai, 200120, China
Research Site
Shenyang, 110016, China
Research Site
Shijiazhuang, 050000, China
Research Site
Tianjin, 300000, China
Research Site
Weifang, 261000, China
Research Site
Wuhan, 430030, China
Research Site
Wuhan, 430040, China
Research Site
Wuhan, 430079, China
Research Site
Xi'an, 710006, China
Research Site
Xi'an, 710061, China
Research Site
Xiamen, 361003, China
Research Site
Xiangyang, 441000, China
Research Site
Xinxiang, 453100, China
Research Site
Zhengzhou, 450008, China
Research Site
Brno, 656 53, Czechia
Research Site
Hořovice, 26831, Czechia
Research Site
Hradec Králové, 500 05, Czechia
Research Site
Olomouc, 77900, Czechia
Research Site
Prague, 120 00, Czechia
Research Site
Prague, 180 00, Czechia
Research Site
Angers, 49100, France
Research Site
Besançon, 25030, France
Research Site
Lille, 59000, France
Research Site
Lyon, 69373, France
Research Site
Marseille, 13273, France
Research Site
Paris, 75005, France
Research Site
Rouen, 76021, France
Research Site
Saint-Herblain, 44805, France
Research Site
Toulouse, 31059, France
Research Site
Villejuif, 94805, France
Research Site
Aachen, 52074, Germany
Research Site
Augsburg, 86150, Germany
Research Site
Berlin, 13125, Germany
Research Site
Cologne, 50937, Germany
Research Site
Dessau, 06847, Germany
Research Site
Düsseldorf, 40225, Germany
Research Site
Erlangen, 91054, Germany
Research Site
Göttingen, DE-37099, Germany
Research Site
Hamburg, 20357, Germany
Research Site
Hanover, 30625, Germany
Research Site
Heidelberg, 69120, Germany
Research Site
Kiel, 24105, Germany
Research Site
Leipzig, 04103, Germany
Research Site
Ludwigsburg, 71640, Germany
Research Site
München, 81675, Germany
Research Site
Münster, 48149, Germany
Research Site
Hong Kong, 150001, Hong Kong
Research Site
Hong Kong, 999077, Hong Kong
Research Site
Budapest, 1082, Hungary
Research Site
Budapest, 1122, Hungary
Research Site
Budapest, 1145, Hungary
Research Site
Debrecen, 4032, Hungary
Research Site
Miskolc, 3526, Hungary
Research Site
Zalaegerszeg, 8900, Hungary
Research Site
Delhi, 110029, India
Research Site
Kolkata, 700160, India
Research Site
Lucknow, 226003, India
Research Site
Mumbai, 400012, India
Research Site
Mumbai, 400052, India
Research Site
Mysuru, 570017, India
Research Site
Nagpur, 440001, India
Research Site
Nashik, 422002, India
Research Site
New Delhi, 110085, India
Research Site
Surat, 396007, India
Research Site
Thiruvananthapuram, 695011, India
Research Site
Jerusalem, 9103102, Israel
Research Site
Jerusalem, 9112001, Israel
Research Site
Petah Tikva, 49100, Israel
Research Site
Ramat Gan, 52621, Israel
Research Site
Tel Aviv, 64239, Israel
Research Site
Bergamo, 24127, Italy
Research Site
Bologna, 40138, Italy
Research Site
Milan, 20132, Italy
Research Site
Milan, 20141, Italy
Research Site
Modena, 41124, Italy
Research Site
Naples, 80131, Italy
Research Site
Padova, 35128, Italy
Research Site
Reggio Emilia, 422122, Italy
Research Site
Rome, 00168, Italy
Research Site
Rozzano, 20089, Italy
Research Site
Chiba, 260-8717, Japan
Research Site
Hidaka-shi, 350-1298, Japan
Research Site
Hirakata-shi, 573-1191, Japan
Research Site
Isehara-shi, 259-1193, Japan
Research Site
Kagoshima, 892-0833, Japan
Research Site
Kashiwa, 227-8577, Japan
Research Site
Kōtoku, 135-8550, Japan
Research Site
Kumamoto, 860-8556, Japan
Research Site
Kyoto, 606-8507, Japan
Research Site
Matsuyama, 791-0280, Japan
Research Site
Nagoya, 464-8681, Japan
Research Site
Nagoya, 466-8560, Japan
Research Site
Nagoya, 467-8602, Japan
Research Site
Osaka, 541-8567, Japan
Research Site
Ota-shi, 373-8550, Japan
Research Site
Sapporo, 003-0804, Japan
Research Site
Sendai, 980-8574, Japan
Research Site
Shinagawa-ku, 142-8666, Japan
Research Site
Suita-shi, 565-0871, Japan
Research Site
Sunto-gun, 411-8777, Japan
Research Site
Takasaki-shi, 370-0829, Japan
Research Site
Tsu, 514-8507, Japan
Research Site
Yokohama, 241-8515, Japan
Research Site
Bandar Puncak Alam, 42300, Malaysia
Research Site
Johor Bahru, 81100, Malaysia
Research Site
Kuala Lumpur, 59100, Malaysia
Research Site
Kuala Selangor, 62250, Malaysia
Research Site
Malacca, 75000, Malaysia
Research Site
Bellavista, CALLAO 2, Peru
Research Site
Jesus Maria, Lima, LIMA 11, Peru
Research Site
Lima, 15036, Peru
Research Site
Lima, LIMA 29, Peru
Research Site
Biała Podlaska, 21-500, Poland
Research Site
Koszalin, 75-581, Poland
Research Site
Lodz, 93-338, Poland
Research Site
Lublin, 20-090, Poland
Research Site
Poznan, 60-569, Poland
Research Site
Poznan, 61-485, Poland
Research Site
Radom, 26-600, Poland
Research Site
Warsaw, 02-781, Poland
Research Site
Coimbra, 3000-075, Portugal
Research Site
Lisbon, 1099-023, Portugal
Research Site
Lisbon, 1998-018, Portugal
Research Site
Matosinhos Municipality, 4454-509, Portugal
Research Site
Porto, 4050-115, Portugal
Research Site
Vila Real, 5000-508, Portugal
Research Site
San Juan, 00918, Puerto Rico
Research Site
Daegu, 41404, South Korea
Research Site
Seongnam-si, 13620, South Korea
Research Site
Seoul, 02841, South Korea
Research Site
Seoul, 03080, South Korea
Research Site
Seoul, 06273, South Korea
Research Site
Seoul, 06351, South Korea
Research Site
Seoul, 3722, South Korea
Research Site
Seoul, 5505, South Korea
Research Site
A Coruña, 15009, Spain
Research Site
Barcelona, 08035, Spain
Research Site
Cáceres, 10003, Spain
Research Site
Granada, 18007, Spain
Research Site
L'Hospitalet de Llobregat, 08908, Spain
Research Site
Madrid, 28040, Spain
Research Site
Madrid, 28041, Spain
Research Site
Málaga, 29010, Spain
Research Site
Pamplona, 31008, Spain
Research Site
Seville, 41013, Spain
Research Site
Valencia, 46006, Spain
Research Site
Zaragoza, 50009, Spain
Research Site
New Taipei City, 23561, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, 704, Taiwan
Research Site
Taipei, 100, Taiwan
Research Site
Taipei, 10449, Taiwan
Research Site
Taipei, 112, Taiwan
Research Site
Taoyuan, 00333, Taiwan
Research Site
Bangkok, 10210, Thailand
Research Site
Bangkok, 10330, Thailand
Research Site
Dusit, 10300, Thailand
Research Site
Hat Yai, 90110, Thailand
Research Site
Muang, 22000, Thailand
Research Site
Ratchathewi, 10400, Thailand
Research Site
Ratchathewi, 10400, Thailand
Research Site
Adapazarı, 54290, Turkey (Türkiye)
Research Site
Altındağ-Ankara, 06230, Turkey (Türkiye)
Research Site
Ankara, 06530, Turkey (Türkiye)
Research Site
Çankaya, 06680, Turkey (Türkiye)
Research Site
Istanbul, 34214, Turkey (Türkiye)
Research Site
Kayseri, 38039, Turkey (Türkiye)
Research Site
Cambridge, CB2 2QQ, United Kingdom
Research Site
Guildford, GU2 7XX, United Kingdom
Research Site
London, SE1 9RT, United Kingdom
Research Site
Manchester, M20 4BX, United Kingdom
Research Site
Oxford, OX3 7LE, United Kingdom
Research Site
Swansea, SA2 8QA, United Kingdom
Research Site
Taunton, TA1 5DA, United Kingdom
Research Site
Truro, TR1 3LJ, United Kingdom
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
AstraZeneca Clinical Study Information Center
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- Open label
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 25, 2024
First Posted
April 24, 2024
Study Start
August 1, 2024
Primary Completion (Estimated)
March 30, 2029
Study Completion (Estimated)
October 18, 2030
Last Updated
May 15, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure